The role of Ivermectin in COVID -19 |management, issues and challenges | ||
| Advances in Pharmacology and Therapeutics Journal | ||
| Article 6, Volume 1, Issue 2, Autumn 2021, Pages 86-88 PDF (197.21 K) | ||
| Document Type: Letter to editor | ||
| DOI: 10.18502/aptj.v1i2.8676 | ||
| Authors | ||
| Reza Bidaki; Habibollah Afshang* ; Mohsen Zabihi | ||
| Abstract | ||
| Why was Ivermectin not mentioned by the medical community in the treatment of COVID-19? In a pandemic, emergency physicians don't have time to wait for validated studies before we try something. An example of a sentence that we hear a lot from parents of children in the community: Here are so many facts to question now: The COVID-19 mandatory injection for children, now going into effect nationwide has me shuddering! Where are the national baseline tests for antibodies for these kids, before they must have this experimental vaccine? It is still experimental people! (Until now, drugs widely used under the mandatory three-year data study by the FDA, are deemed experimental). In the last two years, humans have witnessed a deadly catastrophe called the Corona virus. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has turns to a pandemic all around the world. Despite the importance of vaccination, more efficient drugs are required to treat or manage coronavirus disease-19. According to the Centers for Disease Control and Prevention, 150,000-200,000 new cases of COVID-19 are reported in the United States every day. In the United States, COVID-19 causes more than 2000 deaths a day and more than 300,000 deaths since January 2020(1). Many drugs, including Hydroxychloroquine, have been introduced for treatment, but clinical trials have shown multiple side effects and less benefit in treating the disease with this drug (2). | ||
|
Statistics Article View: 293 PDF Download: 303 |
||